Jump to content

User:Kae0happyeveryday/sandbox

From Wikipedia, the free encyclopedia

Breastfeeding Medicine

[edit]
Drugs transfer from the maternal body into breast milk, subsequently exposing the infant to these substances.

Breastfeeding medicine is a multidisciplinary field focused on optimizing lactation health for mothers and infants. It addresses clinical care, medication safety, and societal support, balancing physiological processes, drug transfer mechanisms (e.g., passive transport, active transport),[1] and individualized risk assessments for medications. Key considerations include psychoactive drugs, opioid therapies (e.g., methadone), analgesics, and galactagogues, with guidelines from organizations like the World Health Organization (WHO) and the Academy of Breastfeeding Medicine (ABM) guiding safe practices.[2]

Research indicates breastfeeding’s benefits, such as enhanced infant cognitive development, reduced maternal postpartum depression, and long-term health advantages. Modern advocacy, revitalized in the 1970s by WHO and UNICEF, established breastfeeding as a pillar of global maternal-child health strategies.[3] Sociocultural attitudes and public policies significantly influence breastfeeding rates, with ongoing efforts to reduce stigma and improve accessibility.[4] Despite progress, disparities in acceptance persist, necessitating culturally sensitive education and systemic support to empower lactating individuals worldwide.[5]

Mechanisms of Drug Transfer During Lactation

[edit]

Each medication should be evaluated individually. While most drugs in breast milk are transferred at low concentrations and usually pose minimal risk to infants, some may be found at higher concentrations.[1]

Passive Transport

[edit]
Drug transport pathways across membranes, including passive diffusion (simple and facilitated) and active transport.

Most drugs enter breast milk through passive diffusion across mammary epithelial cells.There is only a small proportion of drugs with high plasma protein binding that transfer into lactating milk, as only unbounded drugs can diffuse.[6]

The pH of breast milk (7.1–7.2) is slightly more acidic than maternal plasma (7.4), which influences how drugs ionize and are transported. Weakly basic drugs remain non-ionized in plasma, allowing them to readily cross into breast milk. However, once in breast milk, the lower pH increases ionization, trapping these drugs due to reduced permeability of ionized species.[7] In contrast, weakly acidic drugs are mostly ionized in plasma, limiting their passive diffusion into breast milk.[7] For example, a weakly basic drug called diazepam demonstrates this ion-trapping phenomenon, as its concentration in breast milk is twice that of its concentration in plasma. [8]

Active Transport

[edit]

Active transport mechanisms are indicated when the amount of a drug in breast milk exceeds what would be expected from passive transport alone, such as hydromorphone.[9] This process involves membrane-bound transporters such as breast cancer resistance protein (BCRP) and P-glycoprotein (P-gp).

BCRP, which increases during lactation, helps transfer drugs like abacavir and tenofovir alafenamide into breast milk.[10] In contrast, P-gp expression decreases during lactation but may still influence drug movement, as seen with tacrolimus.[11] Moreover, drug transfer can be modulated by transporter expression changes during lactation, including increased organic cation transporter 1 (OCT1) and decreased multidrug resistance-associated protein 1 (MRP1).[12]

Lipid Co-Transport

[edit]

Lipophilic drugs can dissolve into breast milk lipids, particularly during milk fat globule secretion. This transport involves the drug dissolving into fat droplets within the mammary glands or interacting with the fat globules that are secreted into the milk. Hindmilk contains a higher lipid content than foremilk, leading to increased drug concentrations, as seen with duloxetine and mirtazapine.[13][14]

Transcytosis mechanism in apical cells involves vesicular transport of macromolecules across the cellular barrier, combining endocytosis and exocytosis processes.

Transcytosis Transport

Transcytosis facilitates the transfer of large molecules from maternal plasma to breast milk, such as immunoglobulins. This process starts with endocytosis at the basal membrane of mammary epithelial cells, followed by vesicular transport within the cell, and ends with exocytosis into the milk.[15] This transport is mediated mainly by the neonatal Fc receptor (FcRn), particularly for antibodies like immunoglobulin G (IgG). The mechanism is increasingly relevant for therapeutic monoclonal antibodies and large molecule drugs, highlighting the need to evaluate infant exposure during lactation.[16]

Additional Consideration

[edit]

The chemical properties of drugs also influence their transfer from plasma to breast milk, affected by pharmacokinetic factors. Generally, drugs that are non-ionized, have small molecular weights, low volumes of distribution, low maternal serum protein binding, and high lipid solubility are more likely to be excreted into human milk. Infants more easily absorb drugs with long half-lives, which might accumulate in breast milk, and those with high oral bioavailability .[17][18] Additionally, infant age is a crucial factor to consider, as immature kidney function limits their ability to metabolize and excrete certain drugs effectively.[17]

Drug Categories and Safety in Breastfeeding

[edit]

Psychoactive Drugs

[edit]

The effects of psychoactive drugs are classified by The American Academy of Pediatrics (AAP), such as antidepressants, anxiolytics, and antipsychotics, on nursing infants as "unknown but may be of concern" due to limited long-term safety data. The long-term neurodevelopmental impacts of these medications remain uncertain, often complicated by factors such as prenatal exposure, concurrent therapies, and small sample sizes.[19][20]

Many psychoactive drugs, such as selective serotonin reuptake inhibitors (SSRIs) and benzodiazepines, are present in low concentrations in breast milk (less than 2% of the maternal dose).[21] However, some drugs like bupropion,[22] diazepam,[21] fluoxetine,[23] citalopram,[24] lithium,[25] lamotrigine,[26] and venlafaxine,[27] are found in high concentrations in breast milk (over 10% of therapeutic maternal doses). This is often due to prolonged half-lives and immature liver and kidney function of infants.[1] Meanwhile, approximately one-third of psychoactive medications lack sufficient excretion data.[1] Mothers taking these medications should be informed about the benefits and risks of breastfeeding, with careful monitoring of their infant's growth and neurodevelopment.

Opioid Use Disorder Treatments

[edit]

Alcohol and recreational drugs can harm breastfeeding infants through toxic exposure and impair a mother’s ability to care for her child.[28][29] Safe medications to treat addiction or aid smoking cessation are critical for lactating mothers to reduce risks of opioid use disorder.[1] The following is a brief table of treatments for opioid use disorder, their compatibility with breastfeeding, and key points related to them.

Treatment Compatibility with Breastfeeding Key Point
Methadone Compatible Milk concentrations are low (<3% of maternal weight-adjusted dose); supported by the Academy of Breastfeeding Medicine, provided mothers are abstinent and in supervised treatment.[30]
Nicotine replacement therapy Preferred over smoking[30] Short-acting gum or lozenges are recommended as nicotine transfer correlates with maternal usage levels.[31]
Buprenorphine Caution advised Excreted at levels similar to maternal plasma (infant exposure ≤2.4%);[32] warnings due to potential risks to milk production and neonatal viability.
Naltrexone and disulfiram Discouraged Insufficient safety data regarding use during lactation.[1]

Pain Medication

[edit]

Managing pain during lactation requires careful consideration of safety for both mothers and infants. High-risk analgesics can pose significant risks, including respiratory depression and toxicity in nursing infants. Safer alternatives are preferred for mild to moderate pain, especially when methods minimize infant exposure.

High-Risk Analgesics
[edit]
  • Codeine/Hydrocodone: This drug is metabolized via CYP2D6, these opioids risk neonatal toxicity (e.g., apnea, cyanosis) due to ultrarapid metabolism variants, particularly in genetically susceptible populations.[33] Hydrocodone exposure may reach 9% of maternal doses.
  • Oxycodone: This drug is associated with therapeutic infant plasma levels and CNS depression in 20% of exposed neonates.[34]
  • Propoxyphene: This drug linked to apnea, bradycardia, cyanosis, and hypotonia in nursing infants.[35][36] It was also removed from the market due to significant QT prolongation at therapeutic doses.[37]
  • Meperidine: This drug may be related to infant drowsiness and may disrupt breastfeeding.[38] Its active metabolite potentially accumulates in the infant's blood or tissues due to prolonged half-life.[38][39]
Safer Alternatives
[edit]
  • NSAIDs: Ibuprofen and acetaminophen are preferred for mild-moderate pain.[38] Celecoxib, flurbiprofen, and naproxen are compatible (<1% excretion). Ketorolac nasal spray (low transfer) is permissible, while intravenous or oral forms are contraindicated.[1]

Galactagogues

[edit]

Galactagogues (e.g., domperidone, metoclopramide) lack robust evidence for efficacy and safety.[42] Domperidone, which is linked to arrhythmias, is not FDA-approved. Non-pharmacologic strategies like lactation counseling, frequent pumping, and breast massage can be considered.[1]

Clinical Guidelines and Protocols

[edit]

Many protocols in breastfeeding medicine are developed by well-known health organisations to guide healthcare professionals based on extensive research. Organizations like the Academy of Breastfeeding Medicine (ABM), American Academy of Pediatrics (AAP), and the World Health Organization (WHO), regularly publish protocols on dealing with common breastfeeding issues such as mastitis, milk supply insufficiencies, infant feeding difficulties, medication safety during lactation, and special circumstances like prematurity or maternal illness.[2][43] These guidelines are essential resources for healthcare providers, promoting consistent care and informed patient management, even though they are not exhaustive.

Research

[edit]

Overview

[edit]

Research in breastfeeding medicine has deepened the understanding of lactation’s role for both infants and mothers. Numerous studies demonstrate that exclusive breastfeeding during the first six months lowers the incidence of gastrointestinal and respiratory infections, leading to reduced infant morbidity and mortality.[44] This finding is supported by evidence that short-term benefits are accompanied by significant long-term advantages. For example, exclusive breastfeeding is associated with a decreased risk of obesity, diabetes, and cardiovascular disease, while also supporting optimal cognitive development and psychological well-being.[21]

Mothers who breastfeed experience reduced risks of breast and ovarian cancers, type 2 diabetes, hypertension, and other cardiovascular conditions,[45] highlighting the importance of lactation for maternal health. In addition, breastfeeding fosters strong maternal-infant bonding and has been linked to a lower incidence of postpartum depression.[21] Overall, both infants and mothers gain substantial health benefits from exclusive breastfeeding, making it vital for public health and clinical practice.

Research Direction

[edit]

Current research focuses on breastfeeding management in women with chronic diseases, medication safety, and enhancing support programs for diverse populations. Clinical trials are essential for determining effective strategies, validating practices, and assessing innovative interventions to improve breastfeeding rates and maternal-infant health outcomes.[46] Such research informs and refines clinical guidelines, ensuring they remain relevant, practical, and responsive to emerging health scenarios.

Counseling and Support

[edit]

Healthcare professionals trained in breastfeeding medicine provide personalized counseling to manage and overcome common challenges such as latch difficulties, nipple pain, low milk supply, and concerns about infant growth and development. They offer strategies tailored to individual circumstances, enhancing breastfeeding success.

In addition to individual counseling, structured support programs have effectively increased breastfeeding rates worldwide. These programs include peer initiatives, lactation consultations, and the Baby-Friendly Hospital Initiative(BFHI).[47] Support also extends to workplaces, schools, and community spaces, promoting environments that encourage breastfeeding.

History of Breastfeeding Medicine

[edit]
Advertisement for Nestlé baby food published in between 1870-1900.

Breastfeeding medicine appearing as a distinct medical field only occurred in the latter half of the 20th century. This was in response to declining global breastfeeding rates driven by the widespread adoption of formula feeding post-World War II. Historically, breastfeeding was universally recognized as the primary method for infant nourishment until industrialization and aggressive marketing shifted feeding practices in the early to mid-20th century.[48]

The resurgence in breastfeeding advocacy began in the 1970s, supported by international organizations such as WHO and UNICEF. Key initiatives such as the International Code of Marketing of Breast-milk Substitutes adopted in 1981, were turning points toward resetting breastfeeding practices worldwide.[3] Breastfeeding medicine has since matured considerably, now playing a central role in global health strategies aimed at improving maternal and child health, nutrition, and overall survival.[49]

Society and Culture

[edit]

Modern Public Health Campaigns

[edit]
President Gloria Macapagal-Arroyo joins breastfeeding advocates Susan Roth (with 10-month-old Lillian) and Nancy Lem Bailet (with 8-month-old Anna) during the 2009 World Breastfeeding Week celebration at Malacañang's Heroes' Hall.

Public health campaigns have significantly influenced societal perceptions and acceptance of breastfeeding. Initiatives like WHO's World Breastfeeding Week, national breastfeeding awareness campaigns, and advocacy programs promote the health benefits of breastfeeding, counteract misinformation, and reduce the stigma associated with breastfeeding in public. Policy interventions, such as breastfeeding-friendly workplaces, dedicated lactation rooms, and anti-discrimination laws, further support breastfeeding women and increase acceptance and continuation rates worldwide.[4]

Societal Acceptance

[edit]

Despite significant progress, societal acceptance of breastfeeding varies widely across different cultures and regions. In many Western countries, enhanced public awareness and protective legislation have greatly improved societal acceptance, making public breastfeeding increasingly normalized. However, significant cultural, religious, and social taboos persist in various regions globally, impacting maternal choices and experiences. Addressing these challenges requires culturally sensitive education and tailored public health strategies to improve acceptance and support breastfeeding women globally.[5]

Economics

[edit]

Breastfeeding medicine involves economic factors affecting healthcare systems and families. Breastfeeding can reduce healthcare costs by lowering the risks of chronic conditions, thereby diminishing the need for extensive medical interventions.[50] Moreover, it may also reduce expenses with formula feeding and related health conditions.[50]

Investing in lactation support and education can also lead to long-term cost savings and better health outcomes.[51] However, the economic landscape remains complex due to substantial investments in the marketing of formula and ongoing debates over public funding for breastfeeding support initiatives.[4] Government policies and insurance reimbursement models play a critical role in facilitating access to professional lactation consultants and hospital-based breastfeeding promotion programs, influencing resource allocation and policy discussions.[3]

References

[edit]
  1. ^ a b c d e f g h Sachs, Hari Cheryl; COMMITTEE ON DRUGS; Frattarelli, Daniel A. C.; Galinkin, Jeffrey L.; Green, Thomas P.; Johnson, Timothy; Neville, Kathleen; Paul, Ian M.; Van den Anker, John (2013-09-01). "The Transfer of Drugs and Therapeutics Into Human Breast Milk: An Update on Selected Topics". Pediatrics. 132 (3): e796 – e809. doi:10.1542/peds.2013-1985. ISSN 0031-4005.
  2. ^ a b "PROTOCOLS". www.bfmed.org. Retrieved 2025-04-03.
  3. ^ a b c Weltgesundheitsorganisation, ed. (1981). International code of marketing of breastmilk substitutes. Geneva: World Health Organization. ISBN 978-92-4-154160-2.
  4. ^ a b c Rollins, Nigel C; Bhandari, Nita; Hajeebhoy, Nemat; Horton, Susan; Lutter, Chessa K; Martines, Jose C; Piwoz, Ellen G; Richter, Linda M; Victora, Cesar G (January 2016). "Why invest, and what it will take to improve breastfeeding practices?". The Lancet. 387 (10017): 491–504. doi:10.1016/s0140-6736(15)01044-2. ISSN 0140-6736.
  5. ^ a b Amir, Lisa H; Donath, Susan M (September 2008). "Socioeconomic status and rates of breastfeeding in Australia: evidence from three recent national health surveys". Medical Journal of Australia. 189 (5): 254–256. doi:10.5694/j.1326-5377.2008.tb02016.x. ISSN 0025-729X.
  6. ^ Anderson, Philip O. (March 2018). "Drugs in Lactation". Pharmaceutical Research. 35 (3). doi:10.1007/s11095-017-2287-z. ISSN 0724-8741.
  7. ^ a b Worathumrong, N.; Grimes, A. J. (June 1975). "The effect of o-salicylate upon pentose phosphate pathway activity in normal and G6PD-deficient red cells". British Journal of Haematology. 30 (2): 225–231. doi:10.1111/j.1365-2141.1975.tb00536.x. ISSN 0007-1048. PMID 35.
  8. ^ Kelly, Lauren E.; Poon, Shirley; Madadi, Parvaz; Koren, Gideon (September 2012). "Neonatal Benzodiazepines Exposure during Breastfeeding". The Journal of Pediatrics. 161 (3): 448–451. doi:10.1016/j.jpeds.2012.03.003.
  9. ^ Edwards, Jeffrey E.; Rudy, Anita C.; Wermeling, Daniel P.; Desai, Nirmala; McNamara, Patrick J. (February 2003). "Hydromorphone Transfer into Breast Milk After Intranasal Administration". Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. 23 (2): 153–158. doi:10.1592/phco.23.2.153.32081. ISSN 0277-0008.
  10. ^ Ahmadzai, Hilai; Tee, Lisa B. G.; Crowe, Andrew (December 2022). "Are active efflux transporters contributing to infant drug exposure via breastmilk? A longitudinal study". Basic & Clinical Pharmacology & Toxicology. 131 (6): 487–499. doi:10.1111/bcpt.13794. ISSN 1742-7835. PMC 9827846. PMID 36130042.
  11. ^ Zheng, Songmao; Easterling, Thomas R.; Hays, Karen; Umans, Jason G.; Miodovnik, Menachem; Clark, Shannon; Calamia, Justina C.; Thummel, Kenneth E.; Shen, Danny D.; Davis, Connie L.; Hebert, Mary F. (December 2013). "Tacrolimus placental transfer at delivery and neonatal exposure through breast milk". British Journal of Clinical Pharmacology. 76 (6): 988–996. doi:10.1111/bcp.12122. ISSN 0306-5251. PMC 3845323. PMID 23528073.
  12. ^ Alcorn, J.; Lu, X.; Moscow, J.A.; McNamara, P.J. (January 2002). "Transporter Gene Expression in Lactating and Nonlactating Human Mammary Epithelial Cells Using Real-Time Reverse Transcription-Polymerase Chain Reaction". The Journal of Pharmacology and Experimental Therapeutics. 303 (2): 487–496. doi:10.1124/jpet.102.038315.
  13. ^ Boyce, Philip M.; Hackett, L. Peter; Ilett, Kenneth F. (April 2011). "Duloxetine transfer across the placenta during pregnancy and into milk during lactation". Archives of Women's Mental Health. 14 (2): 169–172. doi:10.1007/s00737-011-0215-5. ISSN 1435-1102. PMID 21359876.
  14. ^ Hackett, L. Peter; Ilett, Kenneth F.; Rampono, Jonathan; Kristensen, Judith H.; Kohan, Rolland (August 2006). "Transfer of reboxetine into breastmilk, its plasma concentrations and lack of adverse effects in the breastfed infant". European Journal of Clinical Pharmacology. 62 (8): 633–638. doi:10.1007/s00228-006-0140-0. ISSN 0031-6970.
  15. ^ McManaman, James L.; Neville, Margaret C. (2003-04-29). "Mammary physiology and milk secretion". Advanced Drug Delivery Reviews. 55 (5): 629–641. doi:10.1016/s0169-409x(03)00033-4. ISSN 0169-409X. PMID 12706546.
  16. ^ Einarsdottir, Helga K.; Stapleton, Nigel M.; Scherjon, Sicco; Andersen, Jan Terje; Rispens, Theo; van der Schoot, C. Ellen; Vidarsson, Gestur (2014-09-24). Bayry, Jagadeesh (ed.). "On the Perplexingly Low Rate of Transport of IgG2 across the Human Placenta". PLoS ONE. 9 (9): e108319. doi:10.1371/journal.pone.0108319. ISSN 1932-6203. PMC 4177109. PMID 25251461.{{cite journal}}: CS1 maint: unflagged free DOI (link)
  17. ^ a b Hale, Thomas W. (September 2004). "Maternal medications during breastfeeding". Clinical Obstetrics and Gynecology. 47 (3): 696–711. doi:10.1097/01.grf.0000135653.56778.3f. ISSN 0009-9201. PMID 15326432.
  18. ^ Sachs, Hari Cheryl; COMMITTEE ON DRUGS; Frattarelli, Daniel A. C.; Galinkin, Jeffrey L.; Green, Thomas P.; Johnson, Timothy; Neville, Kathleen; Paul, Ian M.; Van den Anker, John (2013-09-01). "The Transfer of Drugs and Therapeutics Into Human Breast Milk: An Update on Selected Topics". Pediatrics. 132 (3): e796 – e809. doi:10.1542/peds.2013-1985. ISSN 0031-4005.
  19. ^ Gentile, Salvatore (2005). "SSRIs in pregnancy and lactation: emphasis on neurodevelopmental outcome". CNS drugs. 19 (7): 623–633. doi:10.2165/00023210-200519070-00004. ISSN 1172-7047. PMID 15984897.
  20. ^ Gentile, Salvatore (2005). "The safety of newer antidepressants in pregnancy and breastfeeding". Drug Safety. 28 (2): 137–152. doi:10.2165/00002018-200528020-00005. ISSN 0114-5916. PMID 15691224.
  21. ^ a b c d SECTION ON BREASTFEEDING; Eidelman, Arthur I.; Schanler, Richard J.; Johnston, Margreete; Landers, Susan; Noble, Larry; Szucs, Kinga; Viehmann, Laura (2012-03-01). "Breastfeeding and the Use of Human Milk". Pediatrics. 129 (3): e827 – e841. doi:10.1542/peds.2011-3552. ISSN 0031-4005.
  22. ^ Davis, Melinda F.; Miller, Hugh S.; Nolan, Paul E. (February 2009). "Bupropion levels in breast milk for 4 mother-infant pairs: more answers to lingering questions". The Journal of Clinical Psychiatry. 70 (2): 297–298. doi:10.4088/jcp.07l03133. ISSN 1555-2101. PMID 19265649.
  23. ^ Kristensen, J. H.; Ilett, K. F.; Hackett, L. P.; Yapp, P.; Paech, M.; Begg, E. J. (October 1999). "Distribution and excretion of fluoxetine and norfluoxetine in human milk". British Journal of Clinical Pharmacology. 48 (4): 521–527. doi:10.1046/j.1365-2125.1999.00040.x. ISSN 0306-5251. PMC 2014386. PMID 10583022.
  24. ^ Moretti, Myla E. (2009). "Psychotropic drugs in lactation--Motherisk Update 2008". The Canadian Journal of Clinical Pharmacology = Journal Canadien De Pharmacologie Clinique. 16 (1): e49–57. ISSN 1710-6222. PMID 19164846.
  25. ^ Ostrea, Enrique M.; Mantaring, Jacinto Blas; Silvestre, Maria Asuncion (June 2004). "Drugs that affect the fetus and newborn infant via the placenta or breast milk". Pediatric Clinics of North America. 51 (3): 539–579, vii. doi:10.1016/j.pcl.2004.01.001. ISSN 0031-3955. PMID 15157585.
  26. ^ Newport, D. Jeffrey; Pennell, Page B.; Calamaras, Martha R.; Ritchie, James C.; Newman, Melanee; Knight, Bettina; Viguera, Adele C.; Liporace, Joyce; Stowe, Zachary N. (July 2008). "Lamotrigine in breast milk and nursing infants: determination of exposure". Pediatrics. 122 (1): e223–231. doi:10.1542/peds.2007-3812. ISSN 1098-4275. PMC 4714583. PMID 18591203.
  27. ^ Newport, D. Jeffrey; Ritchie, James C.; Knight, Bettina T.; Glover, Bailey A.; Zach, Elizabeth B.; Stowe, Zachary N. (September 2009). "Venlafaxine in human breast milk and nursing infant plasma: determination of exposure". The Journal of Clinical Psychiatry. 70 (9): 1304–1310. doi:10.4088/JCP.08m05001. ISSN 1555-2101. PMID 19607765.
  28. ^ Liebrechts-Akkerman, Germaine; Lao, Oscar; Liu, Fan; van Sleuwen, Bregje E.; Engelberts, Adèle C.; L’Hoir, Monique P.; Tiemeier, Henning W.; Kayser, Manfred (October 2011). "Postnatal parental smoking: an important risk factor for SIDS". European Journal of Pediatrics. 170 (10): 1281–1291. doi:10.1007/s00431-011-1433-6. ISSN 0340-6199. PMC 3175033. PMID 21404101.
  29. ^ Moon, Rachel Y.; Task Force on Sudden Infant Death Syndrome (2011-11-01). "SIDS and Other Sleep-Related Infant Deaths: Expansion of Recommendations for a Safe Infant Sleeping Environment". Pediatrics. 128 (5): 1030–1039. doi:10.1542/peds.2011-2284. ISSN 0031-4005.
  30. ^ a b Flohr, H.; Breull, W. (September 1975). "Effect of etafenone on total and regional myocardial blood flow". Arzneimittel-Forschung. 25 (9): 1400–1403. ISSN 0004-4172. PMID 23.
  31. ^ Wickstrom, R. "Effects of Nicotine During Pregnancy: Human and Experimental Evidence". Current Neuropharmacology. 5 (3): 213–222. doi:10.2174/157015907781695955. PMC 2656811. PMID 19305804.
  32. ^ Ardenne, M.; Reitnauer, P. G. (September 1975). "[Demonstration of tumor inhibiting properties of a strongly immunostimulating low-molecular weight substance. Comparative studies with ifosfamide on the immuno-labile DS carcinosarcoma. Stimulation of the autoimmune activity for approx. 20 days by BA 1, a N-(2-cyanoethylene)-urea. Novel prophylactic possibilities]". Arzneimittel-Forschung. 25 (9): 1369–1379. ISSN 0004-4172. PMID 22.
  33. ^ Anderson, Philip O.; Pochop, Stacey L.; Manoguerra, Anthony S. (May 2003). "Adverse drug reactions in breastfed infants: less than imagined". Clinical Pediatrics. 42 (4): 325–340. doi:10.1177/000992280304200405. ISSN 0009-9228. PMID 12800727.
  34. ^ Seaton, Suzette; Reeves, Mark; McLean, Stuart (June 2007). "Oxycodone as a component of multimodal analgesia for lactating mothers after Caesarean section: relationships between maternal plasma, breast milk and neonatal plasma levels". The Australian & New Zealand Journal of Obstetrics & Gynaecology. 47 (3): 181–185. doi:10.1111/j.1479-828X.2007.00715.x. ISSN 0004-8666. PMID 17550483.
  35. ^ Rigourd, V.; Amirouche, A.; Tasseau, A.; Kintz, P.; Serreau, R. (2008). "Retrospective diagnosis of an adverse drug reaction in a breastfed neonate: liquid chromatography-tandem mass spectrometry quantification of dextropropoxyphene and norpropoxyphene in newborn and maternal hair". Journal of Analytical Toxicology. 32 (9): 787–789. doi:10.1093/jat/32.9.787. ISSN 0146-4760. PMID 19021937.
  36. ^ Naumburg, E. G.; Meny, R. G. (January 1988). "Breast milk opioids and neonatal apnea". American Journal of Diseases of Children (1960). 142 (1): 11–12. doi:10.1001/archpedi.1988.02150010017005. ISSN 0002-922X. PMID 3341293.
  37. ^ Research, Center for Drug Evaluation and (2024-08-09). "FDA Drug Safety Communication: FDA recommends against the continued use of propoxyphene". FDA.
  38. ^ a b c d Bar-Oz, Benjamin; Bulkowstein, Mordechai; Benyamini, Lilach; Greenberg, Revital; Soriano, Ingrid; Zimmerman, Deena; Bortnik, Oxana; Berkovitch, Matitiahu (2003). "Use of antibiotic and analgesic drugs during lactation". Drug Safety. 26 (13): 925–935. doi:10.2165/00002018-200326130-00002. ISSN 0114-5916. PMID 14583068.
  39. ^ Spigset, O.; Hägg, S. (2000). "Analgesics and breast-feeding: safety considerations". Paediatric Drugs. 2 (3): 223–238. doi:10.2165/00128072-200002030-00006. ISSN 1174-5878. PMID 10937472.
  40. ^ Robieux, Isabelle; Koren, Gideon; Vandenbergh, Hilda; Schneiderman, Joyce (January 1990). "Morphine Excretion in Breast Milk and Resultant Exposure of a Nursing Infant". Journal of Toxicology: Clinical Toxicology. 28 (3): 365–370. doi:10.3109/15563659008994437. ISSN 0731-3810.
  41. ^ Bar-Oz, Benjamin; Bulkowstein, Mordechai; Benyamini, Lilach; Greenberg, Revital; Soriano, Ingrid; Zimmerman, Deena; Bortnik, Oxana; Berkovitch, Matitiahu (2003). "Use of Antibiotic and Analgesic Drugs during Lactation:". Drug Safety. 26 (13): 925–935. doi:10.2165/00002018-200326130-00002. ISSN 0114-5916.
  42. ^ Spencer, J. P.; Gonzalez, L. S.; Barnhart, D. J. (2001-07-01). "Medications in the breast-feeding mother". American Family Physician. 64 (1): 119–126. ISSN 0002-838X. PMID 11456429.
  43. ^ "Breastfeeding". www.who.int. Retrieved 2025-04-03.
  44. ^ Victora, Cesar G.; Bahl, Rajiv; Barros, Aluísio J. D.; França, Giovanny V. A.; Horton, Susan; Krasevec, Julia; Murch, Simon; Sankar, Mari Jeeva; Walker, Neff; Rollins, Nigel C. (2016-01-30). "Breastfeeding in the 21st century: epidemiology, mechanisms, and lifelong effect". The Lancet. 387 (10017): 475–490. doi:10.1016/S0140-6736(15)01024-7. ISSN 0140-6736. PMID 26869575.
  45. ^ Chowdhury, Ranadip; Sinha, Bireshwar; Sankar, Mari Jeeva; Taneja, Sunita; Bhandari, Nita; Rollins, Nigel; Bahl, Rajiv; Martines, Jose (December 2015). "Breastfeeding and maternal health outcomes: a systematic review and meta-analysis". Acta Paediatrica (Oslo, Norway: 1992). 104 (467): 96–113. doi:10.1111/apa.13102. ISSN 1651-2227. PMC 4670483. PMID 26172878.
  46. ^ McFadden, Alison; Gavine, Anna; Renfrew, Mary J; Wade, Angela; Buchanan, Phyll; Taylor, Jane L; Veitch, Emma; Rennie, Anne Marie; Crowther, Susan A; Neiman, Sara; MacGillivray, Stephen (2017-02-28). "Support for healthy breastfeeding mothers with healthy term babies". Cochrane Database of Systematic Reviews. 2017 (2). doi:10.1002/14651858.cd001141.pub5. ISSN 1465-1858.
  47. ^ Pérez‐Escamilla, Rafael; Martinez, Josefa L.; Segura‐Pérez, Sofia (2016-02-29). "Impact of the Baby‐friendly Hospital Initiative on breastfeeding and child health outcomes: a systematic review". Maternal & Child Nutrition. 12 (3): 402–417. doi:10.1111/mcn.12294. ISSN 1740-8695.
  48. ^ Stevens, Emily E; Patrick, Thelma E; Pickler, Rita (2009-01-01). "A History of Infant Feeding". Journal of Perinatal Education. 18 (2): 32–39. doi:10.1624/105812409x426314. ISSN 1058-1243.
  49. ^ Fildes, Valerie (October 1990). "Rima D. Apple, Mothers and medicine. A social history of infant feeding, 1890–1950, Madison, University of Wisconsin Press, 1987, 8vo, pp. xv, 261, illus., $39.50, $16.25 (paperback)". Medical History. 34 (4): 464–465. doi:10.1017/s002572730005300x. ISSN 0025-7273.
  50. ^ a b Bartick, Melissa; Reinhold, Arnold (May 2010). "The Burden of Suboptimal Breastfeeding in the United States: A Pediatric Cost Analysis". American Academy of Pediatrics. 125 (5): e1048 – e1056. doi:10.1542/peds.2009-1616.{{cite journal}}: CS1 maint: multiple names: authors list (link) CS1 maint: year (link)
  51. ^ "Global strategy for infant and young child feeding". World Health Organization. 2003-12-22.
Retrieved from "https://en.wikipedia.org/w/index.php?title=User:Kae0happyeveryday/sandbox&oldid=1285580626"